Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 7/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962506 | 0.84 | OGA (0.54) | OGALMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL4755801 | 0.81 | OGA (0.51) | OGALMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL10530529 | 0.81 | LMNA (0.53) | OGALMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL4309394 | 0.80 | OGA (0.48) | OGALMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL8957761 | 0.80 | LMNA (0.45) | OGALMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL573626 | 0.79 | LMNA (0.44) | OGALMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL31697363 | 0.79 | KDM4E (0.54) | OGAMAPTKDM4EALDH1A1RAB9A | |
| SCHEMBL6663539 | 0.78 | — | — | |
| SCHEMBL10498542 | 0.78 | LMNA (0.70) | LMNAMAPTKDM4EALDH1A1RAB9A | |
| SCHEMBL23863880 | 0.78 | OGA (0.49) | OGALMNAMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6441175-B1 | 1-(N'-arylalkylaminoalkyl)aminoisoquinolines: a new class of dopamine receptor subtype | NEUROGEN CORPORATION | 2002-08-27 | — | — | US | disclosed |
| US-20020052496-A1 | Novel 1-(N'-(arylalkylaminoalkyl)) aminoisoquinolines: a new class of dopamine receptor subtype | NEUROGEN CORPORATION | 2002-05-02 | — | — | US | disclosed |
| US-6252077-B1 | PSYCHOLOGICAL, NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-06-26 | — | — | US | disclosed |
| US-6245768-B1 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-06-12 | — | — | US | disclosed |
| US-6031097-A | 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 2000-02-29 | — | — | US | disclosed |
| US-5932729-A | 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1998029410-A1 | 1-(N'-(ARYLALKYLAMINOALKYL)) AMINOISOINDOLES; DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-07-09 | — | — | WO | disclosed |
| US-5744472-A | NEUROLEPTIC AGENTS | NEUROGEN CORPORATION (US) | 1998-04-28 | — | — | US | disclosed |
| US-5656632-A | 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| US-5602168-A | USEFUL IN TREATING VARIOUS NEUROPSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION (US) | 1997-02-11 | — | — | US | disclosed |
| WO-1996039403-A1 | 1-(N'-(ARYLALKYLAMINOALKYL)) AMINOISOINDOLES AS DOPAMINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1996-12-12 | — | — | WO | disclosed |
| EP-0343961-B1 | Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity | AMERICAN HOME PROD (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5482940-A | OBESITY, ALCOHOLISM | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-01-09 | — | — | US | disclosed |
| US-5380725-A | Antipsychotic agents and anxiolytic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-10 | — | — | US | disclosed |
| US-5278160-A | Treating aggressive behavior | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-01-11 | — | — | US | disclosed |
| US-5254552-A | Cognition activators, psychological disorders | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-10-19 | — | — | US | disclosed |
| US-5106849-A | Treating anxiety, depression, psychoses | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-04-21 | — | — | US | disclosed |
| US-5010078-A | Anxiolytic, antidepressant agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-04-23 | — | — | US | disclosed |
| EP-0343961-A2 | Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052496-A1 | Novel 1-(N'-(arylalkylaminoalkyl)) aminoisoquinolines: a new class of dopamine receptor subtype | DRD2, DRD1, CHRNA5 | OGA 4106/4885LMNA 2478/4885MAPT 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.